Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

COVID-19 wasn't a huge issue for the robotic surgical systems leader in the third quarter.

The Most Important Takeaways From Intuitive Surgical's Q3 Results

Better Growth Stock: Facebook or Intuitive Surgical?

The stock price of Intuitive Surgical has seen a rise of around 3% over the last five tradings days after it announced its Q3 results, which were above the street estimates. The company reported revenues of $1.4 billion, up 30% y-o-y, and it compares with our forecast of $1.3 billion and $1.4 bill.

What's Next For Intuitive Surgical Stock?

MongoDB

MercadoLibre

Your chances of making money over the long term are much greater with these stocks.

3 Unstoppable Stocks That Are Better Buys Than Shiba Inu

This market leader beat earnings estimates yet again.

3 Things About Intuitive Surgical That Smart Investors Know.

Intuitive Surgical stock has pulled back a bit from pre-split highs on fears of a Delta Variant revenue pullback due to decreased elective procedures.

Intuitive Surgical Forecast: What Is The Outlook After Recent Stock Split?

Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.

Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study

Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.

Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y

Intuitive Surgical Inc (NASDAQ: ISRG) reported Q3 adjusted EPS of $1.19, slightly ahead of the consensus of $1.17. It reported revenues of $1.403 billion, +30% Y/Y, marginally ahead of Wall Street estimate of $1.39 billion.

Intuitive's Q3 Earnings Slightly Edges Out Expectations

Better-than-expected revenue and earnings are just part of the story for Intuitive.

3 Important Things to Know From Intuitive Surgical's Q3 Update

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q3 2021 Results - Earning Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 0.00% and 0.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q3 Earnings Meet Estimates

Moves reflect growth and help advance minimally invasive care Moves reflect growth and help advance minimally invasive care

Intuitive Announces Executive Leadership Changes

Intuitive Surgical (ISRG) has been struggling lately, but the selling pressure may be coming to an end soon.

Intuitive Surgical (ISRG) Sees Hammer Chart Pattern: Time to Buy?

ISRG is set to give its latest quarterly earnings report on Tuesday, 2021-10-19. Here's what investors need to know before the announcement.

Intuitive Surgical Earnings Preview

SUNNYVALE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the release of preliminary data from 69 subjects participating in the Prospective, Multi-Center Evaluation of the Clinical Utility (PRECIsE) – a post-market, multi-center clinical trial of its Ion endoluminal system.

PRECIsE Clinical Study Preliminary Results Favorable for Intuitive's Ion Endoluminal System for Peripheral Nodule Lung Biopsy

U.S. surgical robotic market is expected to grow at 20.1% CAGR over the next several years, and ISRG will get a huge tailwind from this growth. ISRG is practically printing money, with a large pile of cash accumulated in cash & short-term investments ($4.43 B).

Intuitive Surgical: Future Of Health Care

IDEXX Laboratories

Moderna

Tesla's in the fast lane but these innovators could have more in the tank.

3 Healthcare Stocks That Are Better Than Tesla Right Now

The answer may depend on each investor's time horizon.

Should Intuitive Surgical's Shareholders Worry About the Delta Variant?

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.

What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

Green Thumb Industries Inc.

Pinterest

Investors' cash can go a long way if put to work in these leading growth stocks.

3 No-Brainer Stocks to Invest $1,000 in Right Now

This medical device manufacturer has been a long-term market beater.

What to Watch in Intuitive Surgical's Upcoming Earnings Report

An analyst's downgrade following downbeat comments from management has pushed the robotic surgery company's stock down to an attractive price.

Is Intuitive Surgical a Buy on the Dip?

Any short-term pain should lead to long-term gains with these stocks.

3 Top Stocks to Buy if the Market Crashes

Intuitive Surgical, Inc. (ISRG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for Intuitive Surgical Stock (ISRG)